Clinical Trials Data Microdosing Treatment 
Cannabis Law Report
JULY 25, 2022
million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD). The state agency grant funding followed the successful completion of a phase 1 clinical trial in 80 healthy participants.
Cannabis Law Report
JULY 9, 2022
For Jessica Thornton, who has lived with treatment-resistant depression since her senior year at high school, psychedelics represent a lifeline. Desperate to find any solution, she tried microdosing psilocybin mushrooms after researching the practice online. I felt as if I was in a constant battle with myself. “I
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JUNE 19, 2022
For example, compounds such as psilocybin, mescaline, ibogaine, and LSD are being evaluated in clinical trials, but the compounds themselves are unpatentable because their existence is well documented in the prior art. Originally Published At Microdose. However, that does not mean that the path to patents is closed off.
CannaMD
OCTOBER 7, 2019
In 2011, researchers published cross-sectional data from two population-based surveys including over 50,000 respondents. Prediction 3: The combination of omega-3 supplements and cannabis could be a particularly effective treatment. Are cannabis users really more likely to have better weight-to-height ratios than non-users?
Cannabis Law Report
JUNE 4, 2021
there has never been a better time for new treatment options. Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Rick Doblin, Ph.D, in/rickdoblin/ [link]. in/ronanlevy/. Bia Labate.
Expert insights. Personalized for you.
52 
Let's personalize your content